{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:06:16Z","timestamp":1793315176178,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T00:00:00Z","timestamp":1435622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1038\/nrgastro.2015.97","type":"journal-article","created":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T07:57:10Z","timestamp":1435651030000},"page":"437-445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Modelling hepatitis C therapy\u2014predicting effects of treatment"],"prefix":"10.1038","volume":"12","author":[{"given":"Alan S.","family":"Perelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Guedj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,30]]},"reference":[{"key":"BFnrgastro201597_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1053\/j.gastro.2013.11.007","volume":"146","author":"EJ Gane","year":"2014","unstructured":"Gane, E. J. et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 146, 736\u2013743 (2014).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201597_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/373123a0","volume":"373","author":"DD Ho","year":"1995","unstructured":"Ho, D. D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123\u2013126 (1995).","journal-title":"Nature"},{"key":"BFnrgastro201597_CR3","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/387188a0","volume":"387","author":"AS Perelson","year":"1997","unstructured":"Perelson, A. S. et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188\u2013191 (1997).","journal-title":"Nature"},{"key":"BFnrgastro201597_CR4","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","volume":"271","author":"AS Perelson","year":"1996","unstructured":"Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M. & Ho, D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582\u20131586 (1996).","journal-title":"Science"},{"key":"BFnrgastro201597_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/373117a0","volume":"373","author":"X Wei","year":"1995","unstructured":"Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117\u2013122 (1995).","journal-title":"Nature"},{"key":"BFnrgastro201597_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1126\/science.282.5386.103","volume":"282","author":"AU Neumann","year":"1998","unstructured":"Neumann, A. U. et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282, 103\u2013107 (1998).","journal-title":"Science"},{"key":"BFnrgastro201597_CR7","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1128\/JVI.02612-08","volume":"83","author":"H Dahari","year":"2009","unstructured":"Dahari, H., Sainz, B. Jr., Perelson, A. S. & Uprichard, S. L. Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon. J. Virol. 83, 6383\u20136390 (2009).","journal-title":"J. Virol."},{"key":"BFnrgastro201597_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.mbs.2013.04.012","volume":"245","author":"L Rong","year":"2013","unstructured":"Rong, L. & Perelson, A. S. Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents. Math. Biosci. 245, 22\u201330 (2013).","journal-title":"Math. Biosci."},{"issue":"Suppl. 1","key":"BFnrgastro201597_CR9","first-page":"13","volume":"23","author":"KA Powers","year":"2003","unstructured":"Powers, K. A. et al. Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Sem. Liver Dis. 23 (Suppl. 1), 13\u201318 (2003).","journal-title":"Sem. Liver Dis."},{"key":"BFnrgastro201597_CR10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1053\/jhep.2003.50218","volume":"37","author":"E Herrmann","year":"2003","unstructured":"Herrmann, E., Lee, J.-H., Marinos, G., Modi, M. & Zeuzem, S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37, 1351\u20131358 (2003).","journal-title":"Hepatology"},{"key":"BFnrgastro201597_CR11","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nature03153","volume":"432","author":"NM Dixit","year":"2004","unstructured":"Dixit, N. M., Layden-Almer, J. E., Layden, T. J. & Perelson, A. S. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432, 922\u2013924 (2004).","journal-title":"Nature"},{"key":"BFnrgastro201597_CR12","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1053\/j.gastro.2003.12.002","volume":"126","author":"J-M Pawlotsky","year":"2004","unstructured":"Pawlotsky, J.-M. et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126, 703\u2013714 (2004).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201597_CR13","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/hep.21136","volume":"43","author":"AH Talal","year":"2006","unstructured":"Talal, A. H. et al. Pharmacodynamics of PEG-IFN alpha differentiate HIV\/HCV coinfected sustained virological responders from nonresponders. Hepatology 43, 943\u2013953 (2006).","journal-title":"Hepatology"},{"key":"BFnrgastro201597_CR14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/135965350601100303","volume":"11","author":"E Herrmann","year":"2006","unstructured":"Herrmann, E. et al. Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061. Antivir. Ther. 11, 371\u2013376 (2006).","journal-title":"Antivir. Ther."},{"key":"BFnrgastro201597_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/hep.21657","volume":"46","author":"H Dahari","year":"2007","unstructured":"Dahari, H., Ribeiro, R. M. & Perelson, A. S. Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 46, 16\u201321 (2007).","journal-title":"Hepatology"},{"key":"BFnrgastro201597_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jtbi.2007.03.006","volume":"247","author":"H Dahari","year":"2007","unstructured":"Dahari, H., Lo, A., Ribeiro, R. M. & Perelson, A. S. Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J. Theor. Biol. 247, 371\u2013381 (2007).","journal-title":"J. Theor. Biol."},{"key":"BFnrgastro201597_CR17","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1137\/080714579","volume":"69","author":"TC Reluga","year":"2009","unstructured":"Reluga, T. C., Dahari, H. & Perelson, A. S. Analysis of hepatitis C virus infection models with hepatocyte homeostasis. SIAM J. Appl. Math. 69, 999\u20131023 (2009).","journal-title":"SIAM J. Appl. Math."},{"key":"BFnrgastro201597_CR18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/135965350901400306","volume":"14","author":"H Dahari","year":"2009","unstructured":"Dahari, H., Shudo, E., Cotler, S. J., Layden, T. J. & Perelson, A. S. Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. Antivir. Ther. 14, 459\u2013464 (2009).","journal-title":"Antivir. Ther."},{"key":"BFnrgastro201597_CR19","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jhep.2010.03.019","volume":"53","author":"H Dahari","year":"2010","unstructured":"Dahari, H. et al. Pharmacodynamics of PEG-IFN-alpha-2a in HIV\/HCV co-infected patients: implications for treatment outcomes. J. Hepatol. 53, 460\u2013467 (2010).","journal-title":"J. Hepatol."},{"key":"BFnrgastro201597_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/clpt.2010.238","volume":"89","author":"H Dahari","year":"2011","unstructured":"Dahari, H., Rong, L., Layden, T. J. & Cotler, S. J. Hepatocyte proliferation and hepatitis C virus kinetics during treatment. Clin. Pharmacol. Ther. 89, 353\u2013354 (2011).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFnrgastro201597_CR21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1137\/1.9781611973303.9","volume-title":"2009 SIAM Conference on Mathematics for Industry","author":"J Saltzman","year":"2010","unstructured":"Saltzman, J., Nachbar, R., Panochorchan, P., Stone, J. & Khan, A. in 2009 SIAM Conference on Mathematics for Industry (eds Fields, D. A. & Peters, T. J.) 73\u201383 (Society for Industrial and Applied Mathematics, 2010)."},{"key":"BFnrgastro201597_CR22","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1128\/AAC.06283-11","volume":"56","author":"MB Reddy","year":"2012","unstructured":"Reddy, M. B. et al. Pharmacokinetic\/pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors. Antimicrob. Agents Chemother. 56, 3144\u20133156 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrgastro201597_CR23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/clpt.2014.173","volume":"96","author":"THT Nguyen","year":"2014","unstructured":"Nguyen, T. H. T., Mentr\u00e9, F., Yu, J., Levi, M. & Guedj, J. A pharmacokinetic\u2014viral kinetic model describes the effect of alisporivir monotherapy or in combination with peg-IFN on hepatitis C virologic response. Clin. Pharm. Ther. 96, 599\u2013608 (2014).","journal-title":"Clin. Pharm. Ther."},{"key":"BFnrgastro201597_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/psp4.28","volume":"4","author":"THT Nguyen","year":"2015","unstructured":"Nguyen, T. H. T. & Guedj, J. HCV kinetic models and their implication in drug development. CPT Pharmacometrics Syst. Pharmacol. 4, 231\u2013242 (2015).","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"BFnrgastro201597_CR25","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1007\/s00018-005-5455-y","volume":"63","author":"NM Dixit","year":"2006","unstructured":"Dixit, N. M. & Perelson, A. S. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell. Mol. Life Sci. 63, 832\u2013842 (2006).","journal-title":"Cell. Mol. Life Sci."},{"key":"BFnrgastro201597_CR26","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1053\/j.gastro.2011.12.064","volume":"142","author":"JJ Feld","year":"2012","unstructured":"Feld, J. J. Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals? Gastroenterology 142, 1356\u20131359 (2012).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201597_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1053\/j.gastro.2010.03.037","volume":"139","author":"JJ Feld","year":"2010","unstructured":"Feld, J. J. et al. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 139, 154\u2013162 (2010).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201597_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/gutjnl-2012-303852","volume":"63","author":"Y Rotman","year":"2014","unstructured":"Rotman, Y. et al. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut 63, 161\u2013169 (2014).","journal-title":"Gut"},{"key":"BFnrgastro201597_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.23985","volume":"53","author":"E Thomas","year":"2011","unstructured":"Thomas, E. et al. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 53, 32\u201341 (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro201597_CR30","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/j.1365-2036.2006.02863.x","volume":"23","author":"U Mihm","year":"2006","unstructured":"Mihm, U., Herrmann, E., Sarrazin, C. & Zeuzem, S. Review article: predicting response in hepatitis C virus therapy. Aliment. Pharmacol. Ther. 23, 1043\u20131054 (2006).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrgastro201597_CR31","doi-asserted-by":"publisher","unstructured":"Canini, L. et al. A pharmacokinetic\/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV. Antivir. Ther. http:\/\/dx.doi.org\/10.3851\/IMP2879 .","DOI":"10.3851\/IMP2879"},{"key":"BFnrgastro201597_CR32","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/135965350801300711","volume":"13","author":"E Shudo","year":"2008","unstructured":"Shudo, E., Ribeiro, R. M., Talal, A. H. & Perelson, A. S. A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antivir. Ther. 13, 919\u2013926 (2008).","journal-title":"Antivir. Ther."},{"key":"BFnrgastro201597_CR33","doi-asserted-by":"publisher","first-page":"e1003769","DOI":"10.1371\/journal.pcbi.1003769","volume":"10","author":"JM Conway","year":"2014","unstructured":"Conway, J. M. & Perelson, A. S. A hepatitis C virus infection model with time-varying drug effectiveness: solution and analysis. PLoS Comp. Biol. 10, e1003769 (2014).","journal-title":"PLoS Comp. Biol."},{"key":"BFnrgastro201597_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1517\/17425250902787616","volume":"5","author":"E Shudo","year":"2009","unstructured":"Shudo, E., Ribeiro, R. M. & Perelson, A. S. Modeling hepatitis C virus kinetics under therapy using pharmacokinetic and pharmacodynamic information. Expert Opin. Drug Metab. Toxicol. 5, 321\u2013332 (2009).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"BFnrgastro201597_CR35","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1002\/hep.24272","volume":"53","author":"J Guedj","year":"2011","unstructured":"Guedj, J. & Perelson, A. S. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 53, 1801\u20131808 (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro201597_CR36","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/hep.24788","volume":"55","author":"J Guedj","year":"2012","unstructured":"Guedj, J., Dahari, H., Shudo, E., Smith, P. & Perelson, A. S. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 55, 1030\u20131037 (2012).","journal-title":"Hepatology"},{"key":"BFnrgastro201597_CR37","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3851\/IMP2733","volume":"19","author":"J Guedj","year":"2014","unstructured":"Guedj, J. et al. Analysis of the hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antivir. Ther. 19, 211\u2013220 (2014).","journal-title":"Antivir. Ther."},{"key":"BFnrgastro201597_CR38","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3851\/IMP2806","volume":"20","author":"L Canini","year":"2014","unstructured":"Canini, L. et al. Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy. Antivir. Ther. 20, 149\u2013155 (2014).","journal-title":"Antivir. Ther."},{"key":"BFnrgastro201597_CR39","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10928-014-9363-3","volume":"41","author":"L Canini","year":"2014","unstructured":"Canini, L. & Perelson, A. S. Viral kinetic modeling: state of the art. J. Pharmacokinet. Pharmacodyn. 41, 431\u2013433 (2014).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"BFnrgastro201597_CR40","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature08960","volume":"465","author":"M Gao","year":"2010","unstructured":"Gao, M. et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96\u2013100 (2010).","journal-title":"Nature"},{"key":"BFnrgastro201597_CR41","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/135965350901400402","volume":"14","author":"BS Adiwijaya","year":"2009","unstructured":"Adiwijaya, B. S. et al. Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. Antivir. Ther. 14, 591\u2013595 (2009).","journal-title":"Antivir. Ther."},{"key":"BFnrgastro201597_CR42","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/hep.24788","volume":"55","author":"J Guedj","year":"2012","unstructured":"Guedj, J., Dahari, H., Shudo, E., Smith, P. & Perelson, A. S. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 55, 1030\u20131037 (2012).","journal-title":"Hepatology"},{"key":"BFnrgastro201597_CR43","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1073\/pnas.1203110110","volume":"110","author":"J Guedj","year":"2013","unstructured":"Guedj, J. et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc. Natl Acad. Sci. USA 110, 3991\u20133996 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrgastro201597_CR44","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1086\/315661","volume":"182","author":"AU Neumann","year":"2000","unstructured":"Neumann, A. U. et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J. Infect. Dis. 182, 28\u201335 (2000).","journal-title":"J. Infect. Dis."},{"key":"BFnrgastro201597_CR45","doi-asserted-by":"publisher","first-page":"e1002959","DOI":"10.1371\/journal.pcbi.1002959","volume":"9","author":"L Rong","year":"2013","unstructured":"Rong, L. et al. Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comp. Biol. 9, e1002959 (2013).","journal-title":"PLoS Comp. Biol."},{"key":"BFnrgastro201597_CR46","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1053\/j.gastro.2014.04.021","volume":"147","author":"DR McGivern","year":"2014","unstructured":"McGivern, D. R. et al. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. Gastroenterology 147, 453\u2013462 (2014).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201597_CR47","doi-asserted-by":"publisher","first-page":"5362","DOI":"10.1128\/JVI.03188-14","volume":"89","author":"DR McGivern","year":"2015","unstructured":"McGivern, D. R. et al. Protease inhibitors block multiple functions of the NS3\/4A protease-helicase during the hepatitis C virus life cycle. J. Virol. 89, 5362\u20135370 (2015).","journal-title":"J. Virol."},{"key":"BFnrgastro201597_CR48","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/hep.27333","volume":"60","author":"LW Meredith","year":"2014","unstructured":"Meredith, L. W., Farquhar, M. J., Tarr, A. W. & McKeating, J. A. Type I interferon rapidly restricts infectious hepatitis C virus particle genesis. Hepatology 60, 1891\u20131901 (2014).","journal-title":"Hepatology"},{"key":"BFnrgastro201597_CR49","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1128\/JVI.01304-06","volume":"81","author":"H Dahari","year":"2007","unstructured":"Dahari, H., Ribeiro, R. M., Rice, C. M. & Perelson, A. S. Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. J. Virol. 81, 750\u2013760 (2007).","journal-title":"J. Virol."},{"key":"BFnrgastro201597_CR50","doi-asserted-by":"publisher","first-page":"e1003561","DOI":"10.1371\/journal.ppat.1003561","volume":"9","author":"M Binder","year":"2013","unstructured":"Binder, M. et al. Replication vesicles are load- and choke-points in the hepatitis C virus lifecycle. PLoS Pathog. 9, e1003561 (2013).","journal-title":"PLoS Pathog."},{"key":"BFnrgastro201597_CR51","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/clpt.2010.35","volume":"87","author":"E Snoeck","year":"2010","unstructured":"Snoeck, E. et al. A comprehensive hepatitis C viral kinetic model explaining cure. Clin. Pharmacol. Ther. 87, 706\u2013713 (2010).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFnrgastro201597_CR52","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1053\/j.gastro.2009.10.033","volume":"138","author":"HW Reesink","year":"2010","unstructured":"Reesink, H. W. et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 138, 913\u2013921 (2010).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201597_CR53","doi-asserted-by":"publisher","first-page":"13001","DOI":"10.1128\/JVI.76.24.13001-13014.2002","volume":"76","author":"KJ Blight","year":"2002","unstructured":"Blight, K. J., McKeating, J. A. & Rice, C. M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76, 13001\u201313014 (2002).","journal-title":"J. Virol."},{"key":"BFnrgastro201597_CR54","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1128\/AAC.00289-10","volume":"54","author":"M Robinson","year":"2010","unstructured":"Robinson, M. et al. Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a. Antimicrob. Agents Chemother. 54, 3099\u20133106 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrgastro201597_CR55","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nrd1116","volume":"2","author":"S Farley","year":"2003","unstructured":"Farley, S. A double whammy for hep C. Nat. Rev. Drug Discov. 2, 419 (2003).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrgastro201597_CR56","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1053\/j.gastro.2008.07.023","volume":"135","author":"Y Liang","year":"2008","unstructured":"Liang, Y. et al. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology 135, 1710\u20131718 (2008).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201597_CR57","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1001\/jama.2013.109309","volume":"310","author":"A Osinusi","year":"2013","unstructured":"Osinusi, A. et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 310, 804\u2013811 (2013).","journal-title":"JAMA"},{"key":"BFnrgastro201597_CR58","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jtbi.2010.08.036","volume":"267","author":"J Guedj","year":"2010","unstructured":"Guedj, J. & Neumann, A. U. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. J. Theor. Biol. 267, 330\u2013340 (2010).","journal-title":"J. Theor. Biol."},{"key":"BFnrgastro201597_CR59","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.1128\/AAC.02611-14","volume":"58","author":"C Laouenan","year":"2014","unstructured":"Laouenan, C. et al. Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients. Antimicrob. Agents Chemother. 58, 5332\u20135341 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrgastro201597_CR60","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.dld.2014.12.004","volume":"47","author":"V Centro","year":"2015","unstructured":"Centro, V. et al. Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice. Digestive Liver Dis. 47, 233\u2013241 (2015).","journal-title":"Digestive Liver Dis."},{"key":"BFnrgastro201597_CR61","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(14)61228-9","volume":"385","author":"A Kohli","year":"2015","unstructured":"Kohli, A. et al. Virologic response after 6 week triple-drug regimes for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 385, 1107\u20131113 (2015).","journal-title":"Lancet"},{"key":"BFnrgastro201597_CR62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jviromet.2014.11.027","volume":"214","author":"C Sarrazin","year":"2015","unstructured":"Sarrazin, C. et al. Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct-acting antiviral combination therapy. J. Virol. Methods 214, 29\u201332 (2015).","journal-title":"J. Virol. Methods"},{"key":"BFnrgastro201597_CR63","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","volume":"376","author":"EJ Gane","year":"2010","unstructured":"Gane, E. J. et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376, 1467\u20131475 (2010).","journal-title":"Lancet"},{"key":"BFnrgastro201597_CR64","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/liv.12588","volume":"35","author":"EJ Gane","year":"2015","unstructured":"Gane, E. J. et al. Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study. Liver Intl. 35, 79\u201389 (2015).","journal-title":"Liver Intl."},{"key":"BFnrgastro201597_CR65","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley, K. V. et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 370, 1879\u20131888 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro201597_CR66","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","volume":"385","author":"M Sulkowski","year":"2014","unstructured":"Sulkowski, M. et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV\/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385, 1087\u20131097 (2014).","journal-title":"Lancet"},{"key":"BFnrgastro201597_CR67","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/clpt.2008.21","volume":"84","author":"P Colombatto","year":"2008","unstructured":"Colombatto, P. et al. Early and accurate prediction of Peg-IFNs\/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells. Clin. Pharmacol. Ther. 84, 212\u2013215 (2008).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFnrgastro201597_CR68","doi-asserted-by":"publisher","first-page":"e1002339","DOI":"10.1371\/journal.pcbi.1002339","volume":"8","author":"BS Adiwijaya","year":"2012","unstructured":"Adiwijaya, B. S. et al. A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection. PLoS Comp. Biol. 8, e1002339 (2012).","journal-title":"PLoS Comp. Biol."},{"key":"BFnrgastro201597_CR69","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/hep.26989","volume":"59","author":"J Guedj","year":"2014","unstructured":"Guedj, J. et al. Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in HCV genotype 2\/3 patients. Hepatology 59, 1706\u20131714 (2014).","journal-title":"Hepatology"},{"key":"BFnrgastro201597_CR70","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/hep.21781","volume":"46","author":"TL Kieffer","year":"2007","unstructured":"Kieffer, T. L. et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46, 631\u2013639 (2007).","journal-title":"Hepatology"},{"key":"BFnrgastro201597_CR71","doi-asserted-by":"publisher","first-page":"e1000745","DOI":"10.1371\/journal.pcbi.1000745","volume":"6","author":"BS Adiwijaya","year":"2010","unstructured":"Adiwijaya, B. S. et al. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comp. Biol. 6, e1000745 (2010).","journal-title":"PLoS Comp. Biol."},{"key":"BFnrgastro201597_CR72","doi-asserted-by":"publisher","first-page":"e1002881","DOI":"10.1371\/journal.ppat.1002881","volume":"8","author":"RM Ribeiro","year":"2012","unstructured":"Ribeiro, R. M. et al. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog. 8, e1002881 (2012).","journal-title":"PLoS Pathog."},{"key":"BFnrgastro201597_CR73","doi-asserted-by":"publisher","first-page":"5760","DOI":"10.1128\/JVI.00201-09","volume":"83","author":"JM Cuevas","year":"2009","unstructured":"Cuevas, J. M., Gonz\u00e1lez-Candelas, F., Moya, A. & Sanju\u00e1n, R. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J. Virol. 83, 5760\u20135764 (2009).","journal-title":"J. Virol."},{"key":"BFnrgastro201597_CR74","doi-asserted-by":"publisher","first-page":"30ra32","DOI":"10.1126\/scitranslmed.3000544","volume":"2","author":"L Rong","year":"2010","unstructured":"Rong, L., Dahari, H., Ribeiro, R. M. & Perelson, A. S. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci. Trans. Med. 2, 30ra32 (2010).","journal-title":"Sci. Trans. Med."},{"key":"BFnrgastro201597_CR75","doi-asserted-by":"publisher","first-page":"e1003772","DOI":"10.1371\/journal.pcbi.1003772","volume":"10","author":"EL Haseltine","year":"2014","unstructured":"Haseltine, E. L. et al. Modeling viral evolutionary dynamics after telaprevir-based treatment. PLoS Comp. Biol. 10, e1003772 (2014).","journal-title":"PLoS Comp. Biol."},{"key":"BFnrgastro201597_CR76","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s11538-012-9736-y","volume":"74","author":"L Rong","year":"2012","unstructured":"Rong, L., Ribeiro, R. M. & Perelson, A. S. Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor. Bull. Math. Biol. 74, 1789\u20131817 (2012).","journal-title":"Bull. Math. Biol."},{"key":"BFnrgastro201597_CR77","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1128\/JVI.02144-06","volume":"81","author":"T Schaller","year":"2007","unstructured":"Schaller, T. et al. Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. J. Virol. 81, 4591\u20134603 (2007).","journal-title":"J. Virol."},{"key":"BFnrgastro201597_CR78","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1128\/JVI.01748-06","volume":"81","author":"DM Tscherne","year":"2007","unstructured":"Tscherne, D. M. et al. Superinfection exclusion in cells infected with hepatitis C virus. J. Virol. 81, 3693\u20133703 (2007).","journal-title":"J. Virol."},{"key":"BFnrgastro201597_CR79","doi-asserted-by":"publisher","first-page":"13354","DOI":"10.1128\/JVI.02465-13","volume":"87","author":"B Webster","year":"2013","unstructured":"Webster, B., Ott, M. & Greene, W. C. Evasion of superinfection exclusion and elimination of primary viral RNA by an adapted strain of hepatitis C virus. J. Virol. 87, 13354\u201313369 (2013).","journal-title":"J. Virol."},{"key":"BFnrgastro201597_CR80","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/hep.27361","volume":"61","author":"C Hedskog","year":"2015","unstructured":"Hedskog, C. et al. Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir\/ribavirin. Hepatology 61, 471\u2013480 (2015).","journal-title":"Hepatology"},{"key":"BFnrgastro201597_CR81","doi-asserted-by":"publisher","first-page":"e1002588","DOI":"10.1371\/journal.pcbi.1002588","volume":"8","author":"KA Pawelek","year":"2012","unstructured":"Pawelek, K. A. et al. Modeling within-host dynamics of influenza virus infection including immune responses. PLoS Comp. Biol. 8, e1002588 (2012).","journal-title":"PLoS Comp. Biol."},{"key":"BFnrgastro201597_CR82","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","volume":"47","author":"WR Greco","year":"1995","unstructured":"Greco, W. R., Bravo, G. & Parsons, J. C. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47, 331\u2013385 (1995).","journal-title":"Pharmacol. Rev."},{"key":"BFnrgastro201597_CR83","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/10543400701199593","volume":"17","author":"JJ Lee","year":"2007","unstructured":"Lee, J. J., Kong, M., Ayers, G. D. & Lotan, R. Interaction index and different methods for determining drug interaction in combination therapy. J. Biopharm. Stat. 17, 461\u2013480 (2007).","journal-title":"J. Biopharm. Stat."},{"key":"BFnrgastro201597_CR84","doi-asserted-by":"publisher","first-page":"S464","DOI":"10.1016\/S0168-8278(12)61184-2","volume":"56","author":"G Cheng","year":"2012","unstructured":"Cheng, G. et al. Antiviral activity and resistance profile of the novel HCV NS5A inhibitor GS-5885. J. Hepatol. 56, S464 (2012).","journal-title":"J. Hepatol."},{"key":"BFnrgastro201597_CR85","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/cid\/civ170","volume":"60","author":"S Sidharthan","year":"2015","unstructured":"Sidharthan, S. et al. Utility of hepatitis C viral load monitoring on directly acting antiviral therapy. Clin. Infect. Dis. 60, 1743\u20131751 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrgastro201597_CR86","doi-asserted-by":"publisher","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","volume":"9","author":"A Saez-Cirion","year":"2013","unstructured":"Saez-Cirion, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211 (2013).","journal-title":"PLoS Pathog."},{"key":"BFnrgastro201597_CR87","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1073\/pnas.1419162112","volume":"112","author":"JM Conway","year":"2015","unstructured":"Conway, J. M. & Perelson, A. S. Post-treatment control of HIV infection. Proc. Natl. Acad Sci. USA 112, 5467\u20135472 (2015).","journal-title":"Proc. Natl. Acad Sci. USA"},{"key":"BFnrgastro201597_CR88","doi-asserted-by":"publisher","first-page":"6037","DOI":"10.1073\/pnas.90.13.6037","volume":"90","author":"YK Shimizu","year":"1993","unstructured":"Shimizu, Y. K., Purcell, R. H. & Yoshikura, H. Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro. Proc. Natl Acad. Sci. USA 90, 6037\u20136041 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrgastro201597_CR89","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jhep.2013.02.009","volume":"59","author":"E Lawitz","year":"2013","unstructured":"Lawitz, E. et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450\/r, ABT-072) and ribavirin in IL28B C\/C patients with chronic hepatitis C genotype 1. J. Hepatol 59, 18\u201323 (2013).","journal-title":"J. Hepatol"},{"key":"BFnrgastro201597_CR90","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3851\/IMP2659","volume":"18","author":"V Soriano","year":"2013","unstructured":"Soriano, V. et al. Very late relapse after discontinuation of antiviral therapy for chronic hepatitis, C. Antiviral therapy 18, 1033\u20131035 (2013).","journal-title":"Antiviral therapy"},{"key":"BFnrgastro201597_CR91","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3851\/IMP2753","volume":"19","author":"P Barreiro","year":"2014","unstructured":"Barreiro, P. et al. Very late HCV relapse following triple therapy for hepatitis, C. Antivir. Ther. 19, 723\u2013724 (2014).","journal-title":"Antivir. Ther."},{"key":"BFnrgastro201597_CR92","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.gastro.2010.10.048","volume":"140","author":"NS Veerapu","year":"2011","unstructured":"Veerapu, N. S., Raghuraman, S., Liang, T. J., Heller, T. & Rehermann, B. Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. Gastroenterology 140, 676\u2013685 (2011).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201597_CR93","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1093\/infdis\/jiu325","volume":"10","author":"JC Lin","year":"2014","unstructured":"Lin, J. C. et al. Interferon \u03b3-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: Implications for the innate immune response. J. Infect. Dis. 10, 1881\u20131885 (2014).","journal-title":"J. Infect. Dis."},{"key":"BFnrgastro201597_CR94","unstructured":"Food and Drug Administration Center for Drug Evaluation Research. Guidance for industry chronic Hepatitis C virus infection: developing direct-acting antiviral drugs for treatment [online] , (2013)."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2015.97.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2015.97","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2015.97.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T19:02:39Z","timestamp":1748458959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2015.97"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,30]]},"references-count":94,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["BFnrgastro201597"],"URL":"https:\/\/doi.org\/10.1038\/nrgastro.2015.97","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,30]]},"assertion":[{"value":"30 June 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.S.P and J.G. have consulted for Gilead Sciences. A.S.P has also consulted for Achillion Pharmaceuticals and Bristol-Myers Squibb.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}